IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) represents the most common form of non-Hodgkin lymphoma (NHL) that is still incurable in a large fraction of patients. Tetraspanin CD37 is highly expressed on mature B lymphocytes, and multiple CD37-targeting therapies are under clinical development for NHL. How...

Full description

Saved in:
Bibliographic Details
Published in:Blood advances 2022-04, Vol.6 (7), p.2254-2266
Main Authors: Elfrink, Suraya, ter Beest, Martin, Janssen, Luuk, Baltissen, Marijke P., Jansen, Pascal W.T.C., Kenyon, Angelique N., Steen, Raymond M., de Windt, Daynelys, Hagemann, Philipp M., Hess, Corine, van Spronsen, Dick-Johan, Hoevenaars, Brigiet, van der Spek, Ellen, Xu-Monette, Zijun Y., Young, Ken H., Kaffa, Charlotte, Bervoets, Sander, van Heek, Jolien, Hesius, Eva, de Winde, Charlotte M., Vermeulen, Michiel, van den Brand, Michiel, Scheijen, Blanca, van Spriel, Annemiek B.
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - genetics
B-Lymphocytes - metabolism
Humans
Interferon Regulatory Factors - genetics
Interferon Regulatory Factors - metabolism
Lymphoid Neoplasia
Lymphoma, Large B-Cell, Diffuse - pathology
Proteomics
Tetraspanins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diffuse large B-cell lymphoma (DLBCL) represents the most common form of non-Hodgkin lymphoma (NHL) that is still incurable in a large fraction of patients. Tetraspanin CD37 is highly expressed on mature B lymphocytes, and multiple CD37-targeting therapies are under clinical development for NHL. However, CD37 expression is nondetectable in ∼50% of DLBCL patients, which correlates with inferior treatment outcome, but the underlying mechanisms for differential CD37 expression in DLBCL are still unknown. Here, we investigated the regulation of the CD37 gene in human DLBCL at the (epi-)genetic and transcriptional level. No differences were observed in DNA methylation within the CD37 promoter region between CD37-positive and CD37-negative primary DLBCL patient samples. On the contrary, CD37-negative DLBCL cells specifically lacked CD37 promoter activity, suggesting differential regulation of CD37 gene expression. Using an unbiased quantitative proteomic approach, we identified transcription factor IRF8 to be significantly higher expressed in nuclear extracts of CD37-positive as compared with CD37-negative DLBCL. Direct binding of IRF8 to the CD37 promoter region was confirmed by DNA pulldown assay combined with mass spectrometry and targeted chromatin immunoprecipitation (ChIP). Functional analysis indicated that IRF8 overexpression enhanced CD37 protein expression, while CRISPR/Cas9 knockout of IRF8 decreased CD37 levels in DLBCL cell lines. Immunohistochemical analysis in a large cohort of primary DLBCL (n = 206) revealed a significant correlation of IRF8 expression with detectable CD37 levels. Together, this study provides new insight into the molecular mechanisms underlying differential CD37 expression in human DLBCL and reveals IRF8 as a transcriptional regulator of CD37 in B-cell lymphoma. •IRF8 is a transcriptional regulator of CD37 expression in DLBCL, which may have implications for anti-CD37 therapies.•Patients with poor prognostic CD37-negative DLBCL show significantly lower IRF8 expression compared with patients with CD37-positive DLBCL. [Display omitted]
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2021004366